10-Q: Hologic Q1 Earnings Mixed Amidst Pending Blackstone/TPG Merger

Hologic reports mixed first-quarter financial results with a slight revenue increase, a dip in net income, and a significant pending acquisition by Blackstone and TPG.

Summary

• Total revenues for the three months ended December 27, 2025, increased by 2.5% to $1,047.8 million, up from $1,021.8 million in the prior year period.
• Net income decreased by 10.9% to $179.1 million, compared to $201.0 million in the corresponding prior year quarter.
• Diluted net income per common share was $0.79, a decrease from $0.87 in the prior year period.
• The company entered into a definitive agreement on October 21, 2025, to be acquired by Blackstone Inc. and TPG Capital for up to $79.00 per share ($76.00 cash plus a non-tradable contingent value right of up to $3.00).
• Diagnostics product revenues decreased by 0.8% to $433.2 million, primarily due to lower SARS-CoV-2, Aptima CT/NG, and HPV assay sales, partially offset by increased BV/CV assays and Fusion open access assays.
• Breast Health product revenues decreased by 2.2% to $205.1 million, mainly due to lower sales of digital mammography systems and a stop-ship/recall of Brevera 9 Gauge Needles.
• GYN Surgical product revenues increased by 8.0% to $177.4 million, driven by the Gynesonics acquisition ($9.1 million contribution), MyoSure devices, and Fluent Fluid Management products.
• Skeletal Health product revenues surged by 124.3% to $15.7 million, primarily due to increased Horizon DXA system volumes after a temporary stop-ship was resolved.
• Operating income increased by 3.1% to $237.0 million, up from $229.8 million in the prior year quarter.
• Net cash provided by operating activities was $229.9 million, an increase from $189.3 million in the prior year period.
• The BioZorb litigation was settled on January 7, 2026, with the settlement amount fully covered by insurance, expecting no financial liability for the company.
• Merger-related class action and individual lawsuits were filed on January 14-15, 2026, alleging proxy statement omissions, which the company believes are without merit.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While revenue growth and a significant acquisition provide positive momentum, the decline in net income, product recall, and merger-related litigation introduce notable uncertainties.

Positives

• Total revenues increased by 2.5% to $1,047.8 million, demonstrating overall top-line growth.
• Operating income grew by 3.1% to $237.0 million, indicating improved operational efficiency.
• Net cash provided by operating activities significantly increased to $229.9 million from $189.3 million, reflecting strong cash generation.
• Net cash used in financing activities decreased substantially to $10.7 million from $537.0 million, indicating reduced outflows for share repurchases.
• The GYN Surgical segment experienced an 8.7% revenue increase, boosted by the Gynesonics acquisition and growth in MyoSure and Fluent Fluid Management products.
• Skeletal Health revenues dramatically increased by 69.0%, primarily due to the resolution of a stop-ship on Horizon DXA systems.
• The BioZorb litigation was settled, with the company expecting no financial liability as the settlement is fully covered by insurance.
• Service and other revenues increased by 6.1%, driven by an expanded installed base of digital mammography systems and lower field service expenses.

Negatives

• Net income decreased by 10.9% to $179.1 million, and diluted EPS fell by 9.2% to $0.79, indicating reduced profitability.
• Diagnostics product revenues decreased by 0.8%, primarily due to lower sales of SARS-CoV-2 assays and Aptima CT/NG and HPV assays.
• Breast Health product revenues decreased by 2.2%, attributed to longer sales cycles for digital mammography systems and a stop-ship/recall of Brevera 9 Gauge Needles due to particle dislodgement.
• GYN Surgical operating income decreased by 30.9%, primarily due to increased operating expenses, higher tariffs, and lower margins from Gynesonics products.
• The domestic NovaSure market is shrinking due to increased use of alternative therapies, impacting GYN Surgical revenues.
• Increased tariff costs contributed to higher cost of product revenues, impacting gross margin.
• Merger-related lawsuits have been filed by purported stockholders alleging disclosure deficiencies in proxy statements, creating legal uncertainty.
• Other income decreased significantly from $24.0 million to $0.6 million, primarily due to lower foreign currency exchange gains compared to the prior year.

Risks

• The proposed merger with Blackstone and TPG may face delays in obtaining governmental and regulatory approvals or may be abandoned.
• Stockholders may not approve the merger, leading to its termination.
• The merger could disrupt management time from ongoing business operations.
• Announcements related to the merger could adversely affect the market price of common stock.
• Unexpected costs or expenses may result from the merger.
• Litigation related to the merger could have adverse effects.
• The merger and its announcement could negatively impact the ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, and stockholders.
• Holders of contingent value rights (CVRs) may receive less-than-anticipated payments.
• Ability to obtain and maintain regulatory approvals and compliance with evolving regulations and quality standards is uncertain.
• Products may contain undetected errors or defects or otherwise not perform as anticipated, as seen with the Brevera 9 Gauge Needles.
• Impact and costs of investigative and legal proceedings and compliance risks.
• Impact of future tax legislation.
• Ability to successfully manage ongoing organizational and strategic changes, including attracting and retaining key employees.
• Ongoing and possible future effects of global challenges, including macroeconomic uncertainties (inflation, rising interest rates, bank failures, wars, recession concerns) on customers, suppliers, and business.
• Effect of worldwide political and social uncertainty and divisions, impacting trade regulations, tariffs, and costs.
• Risks related to conducting business internationally.
• Ability to execute acquisitions and realize anticipated benefits.
• Development of new or improved competitive technologies and products.
• Ability to predict accurately the demand for products and develop successful market strategies.
• Effect of consolidation in the healthcare industry.
• Coverage and reimbursement decisions of third-party payors.
• Uncertainty of the impact of cost containment efforts and federal healthcare reform legislation.
• Potential cybersecurity threats and targeted computer crime.
• Possibility of interruptions or delays at manufacturing facilities or failure to secure alternative suppliers.
• Ongoing and possible future effects of supply chain constraints, including availability and cost inflation of raw materials and components.
• Ability to consolidate manufacturing and other operations on a timely basis and within budget without disrupting business.
• Potential negative impacts from climate change or other environmental, social, and governance (ESG) matters.
• Ability to meet production and delivery schedules for products.
• Effect of any future public health pandemic or other crises.
• Ability to protect intellectual property rights.
• Risks related to anticipated trends in financial condition or results of operations, including interest rate and foreign currency exchange fluctuations.
• Risks related to estimated asset and liability values.
• Risks related to compliance with covenants in debt agreements.
• Risks related to liquidity, capital resources, and their adequacy.

Future Outlook

The proposed merger with Blackstone and TPG Capital is expected to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals. The stop-ship of Brevera 9 Gauge Needles is expected to be prolonged as the company assesses the issue and re-engineers the manufacturing process. The company is discontinuing the sale of its Fluoroscan Insight FD systems in fiscal 2026. Management believes that current cash, short-term investments, cash flows from operations, and available credit will provide sufficient funds for existing commitments and normal operations over the next twelve months.

Management Comments

• Management believes the allegations in the merger-related lawsuits are without merit.
• The company expects to bear no financial liability related to the BioZorb litigation settlement agreement, as it is fully covered by insurance.

Industry Context

StockSavvy.ai notes the ongoing consolidation in the healthcare industry, exemplified by Hologic's pending acquisition by private equity firms Blackstone and TPG. This trend often reflects a desire for operational efficiencies and strategic repositioning away from public market pressures. The challenges in diagnostics, particularly the normalization of SARS-CoV-2 assay sales, align with broader market shifts post-pandemic. The issues in Breast Health, such as longer sales cycles for digital mammography and the Brevera product recall, highlight the intense competition and regulatory scrutiny prevalent in the medical device sector. The shrinking ablation market for NovaSure in GYN Surgical underscores the continuous need for innovation and adaptation to evolving treatment paradigms and competitive alternative therapies.

Legal Proceedings

• The BioZorb litigation was settled on January 7, 2026, with no admission of liability and the settlement amount fully covered by insurance.
• Class action and individual lawsuits were filed on January 14 and 15, 2026, respectively, by purported stockholders against the company and its board of directors, alleging omissions in the preliminary and definitive proxy statements related to the Blackstone/TPG merger.
• Demand letters from purported stockholders regarding disclosure deficiencies in merger proxy statements were received starting December 15, 2025.

Stakeholder Impact

• Shareholders will be impacted by the proposed merger, receiving cash and a contingent value right, but also face uncertainty from merger-related litigation.
• Employees, particularly key personnel, are subject to retention bonus programs to ensure continued commitment during the merger transition.
• Customers in the Breast Health segment are affected by the stop-ship and recall of Brevera 9 Gauge Needles, potentially impacting product availability and trust.
• The BioZorb litigation settlement removes a significant legal overhang, benefiting the company's financial stability and reputation.

Next Steps

• The proposed merger with Blackstone and TPG Capital is expected to close in the first half of calendar year 2026, pending stockholder and regulatory approvals.
• The company will continue to assess the issue with Brevera 9 Gauge Needles and re-engineer the manufacturing process, which is expected to prolong the stop-ship.
• The company will continue to defend against the merger-related lawsuits filed by purported stockholders.
• The company will discontinue the sale of its Fluoroscan Insight FD systems in fiscal 2026.

Key Dates

Recommendation

The pending acquisition by Blackstone and TPG Capital at a fixed price provides a clear valuation floor for the stock, suggesting a 'hold' for investors awaiting the merger's completion. However, the decline in net income, operational challenges in key segments like Breast Health (Brevera recall), and ongoing merger-related litigation introduce uncertainties that temper a 'buy' recommendation. The company's strong cash position and resolution of the BioZorb litigation are positive, but the overall picture is one of transition with both opportunities and risks.

Keywords

Hologic, HOLX, Blackstone, TPG Capital, Merger, Acquisition, Medical Devices, Diagnostics, Breast Health, GYN Surgical, Skeletal Health, SEC Filing, 10-Q, Quarterly Report, Financial Results, Healthcare, Biotechnology, Medical Imaging, Women's Health